Investor Relations :: Benitec Biopharma Inc. (BNTC)

Latest News

May 15, 2023

Benitec Biopharma Releases Third Quarter 2023 Financial Results and Provides Operational Update

View Press Release

May 8, 2023

Benitec Biopharma to Present at the OPMD International Conference

May 8, 2023

Benitec Biopharma to Present at the JMP Securities Life Sciences Conference

View All News

Corporate Presentation, January 2023

View Presentation

OPMD International Conference

View All

Q3 2023

Quarter Ended Mar 31, 2023

Earnings Release

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending Jun 30, 2022

Company Overview

Benitec Biopharma Inc. is a development-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary platform, called DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD), and Chronic Hepatitis B.

View Management Team View Board of Directors

Investor Contact Information

Company

Benitec Biopharma Inc.
3940 Trust Way
Hayward, CA 94545

Investor Relations

William Windham
VP, Solebury Trout
T: 646-378-2946
wwindham@soleburytrout.com

Transfer Agent

Computershare Investor Services
P.O. Box 505005
Louisville, KY 40233-5005
T: 781-575-3100